- CognivAiD offers a much-needed option to meet the unmet needs of people with vascular dementia.
- CognivAiD demonstrated significant and clinically meaningful disease-modifying effects with a favorable safety profile in clinical trials based on the VaDAS-Cog and ADCS-CGIC scales.
- CognivAiD has a unique ‘multimodal mechanism of action’ and strengthens Moleac’s commitment to developing innovative, scientifically proven formulations for patients with neurological disorders.
SINGAPORE, Jan. 16, 2023 (GLOBE NEWSWIRE) — Moleac announced on 29thth October 2022 will see the launch of CognivAiD™, the first-to-market product specifically for Vascular Dementia (VaD). CognivAiD, an optimized formulation of active extracts from ginkgo biloba, ginseng and saffron, has shown significant and clinically meaningful disease-modifying effects in patients with VaD.
Commenting on the launch, Moleac CEO David Picard said: Over the past 20 years, we have built a unique platform to develop and bring to patients innovative medicines that meet neurological needs. This is accomplished with its flagship product, NeuroAiD™ II, which is currently benefiting patients in over 35 countries. Our current strategy is to leverage our expertise, infrastructure and partners to bring more treatments to people suffering from loss of brain function. We are very proud to launch CognivAiD, which fills a huge gap in ”
Over 55 million people worldwide currently have dementia, with over 10 million cases occurring each year. This poses a huge financial and economic burden, equivalent to a global cost of $1.3 trillion annually, which is expected to rise to $2.8 trillion by 2030.1Vascular dementia is the second most common subtype of dementia after Alzheimer’s disease and accounts for 15-30% of all dementia cases.2.
Current treatment options for VaD include acetylcholinesterase inhibitors (AChE inhibitors), such as donepezil, and NMDA antagonists, such as memantine. However, these options do not specifically target the primary mechanism of VaD.
“There are currently few treatment options available for patients with VaD. Existing options have modest and non-specific documented benefits, and may have unwanted side effects in this frail population. Thanks to years of research in clinical trials, CognivAiD is now available as a new therapeutic option, slowing cognitive decline in patients with VaD and helping them maintain daily activities: vascular protection, vasoregulation, and neuroinflammation. It targets the complex disease pathways of VaD through its regulatory properties, whose efficacy and safety are well established in rigorous clinical trials published in peer-reviewed journals. We are proud to provide access to CognivAiD, a new, safe and effective treatment that will benefit VaD patients and their caregivers.”
For more information, please visit www.cognivaid.com.
CognivAiD is an evidence-based formulation containing active extracts from Croci Stigma, Ginkgo Folium, and Ginseng Radix et Rhizoma that have been shown to be safe and effective in treating vascular dementia.
Moleac is a biopharmaceutical company committed to helping patients and families get their lives back on track. Headquartered in Singapore, the company is a scientifically proven, innovative company that fills therapeutic gaps and addresses unmet needs in patients with neurological disorders such as stroke, traumatic brain injury and dementia. We are dedicated to developing formulations.
Moleac’s flagship product, NeuroAiD™ II, reaches more than 30,000 patients in more than 35 countries each year. The company’s new product for vascular dementia, CognivAiD™, was launched in October 2022.
For more information, please visit www.moleac.com.
Press Name: Clement Dif
Phone: +65 6211 3710